Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer
As a leading cause of death, cancer is a major public health problem with approxmiately 12.7 million new cases a year in the USA alone. A focus of oncology is palliative care, with the goal of alleviating pain, nausea and vomiting in patients with advanced-stage disease. In Israel, license for medical cannabis purchase and consumption has become available to cancer patients for the palliation of these symptoms under doctor recommendation since 2007. A recent study has demonstrated the promising safety and efficacy of this therapy.
Data routinely collected as part of a treatment program of 2970 cancer patients receiving medical cannabis between 2015 and 2017 were analyzed. Patients in this cohort represented a wide range of cancers, with the most frequent types being breast, lung, pancreatic and colorectal. 51.2% of the patients were at the most advanced stage of disease progression, and 26.7% reported previous experience with cannabis. The main reason these patients received cannabis therapy was to address sleep problems, intense pain, weakness, nausea and lack of appetite.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →At the six-month follow-up, 24.9% of the patients had passed away and 18.8% had stopped the treatment. Of the remaining, 60.6% responded to follow-up surveys, among which 95.9% reported an improvement in their condition, 43.7% reported no change and only 0.3% reported deterioration in their medical condition. Only 30.3% indicated that they experienced some types of unwanted effects. Overall, through this study, the author demonstrated that cannabis seems to be a well tolerated, effective and safe palliative treatment option to help cancer patients cope with common disease symptoms and side-effects of chemotherapy.
